Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) is a nucleotide analog and the active metabolite of the chemotherapeutic agents 5-fluorouracil (5-FU) and floxuridine. It acts as a suicide inhibitor of thymidylate synthase, an enzyme essential for DNA synthesis. By forming a stable covalent complex with thymidylate synthase in the presence of its cofactor, FdUMP irreversibly inhibits the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate, leading to depletion of thymidine nucleotides required for DNA replication and repair. This results in cell cycle arrest and apoptosis, particularly affecting rapidly dividing tumor cells. FdUMP is primarily used in cancer research and has been investigated as an antitumor agent due to its potent inhibition of DNA synthesis[4][6][1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-fluoro-2'-deoxyuridine-5'-monophosphate.